219 related articles for article (PubMed ID: 10993933)
1. Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81.
Allander T; Drakenberg K; Beyene A; Rosa D; Abrignani S; Houghton M; Widell A; Grillner L; Persson MAA
J Gen Virol; 2000 Oct; 81(Pt 10):2451-2459. PubMed ID: 10993933
[TBL] [Abstract][Full Text] [Related]
2. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.
Hadlock KG; Lanford RE; Perkins S; Rowe J; Yang Q; Levy S; Pileri P; Abrignani S; Foung SK
J Virol; 2000 Nov; 74(22):10407-16. PubMed ID: 11044085
[TBL] [Abstract][Full Text] [Related]
3. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus.
Johansson DX; Voisset C; Tarr AW; Aung M; Ball JK; Dubuisson J; Persson MA
Proc Natl Acad Sci U S A; 2007 Oct; 104(41):16269-74. PubMed ID: 17911260
[TBL] [Abstract][Full Text] [Related]
4. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding.
Triyatni M; Vergalla J; Davis AR; Hadlock KG; Foung SK; Liang TJ
Virology; 2002 Jun; 298(1):124-32. PubMed ID: 12093180
[TBL] [Abstract][Full Text] [Related]
5. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding.
Patel AH; Wood J; Penin F; Dubuisson J; McKeating JA
J Gen Virol; 2000 Dec; 81(Pt 12):2873-2883. PubMed ID: 11086118
[TBL] [Abstract][Full Text] [Related]
6. Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs.
Burioni R; Bugli F; Mancini N; Rosa D; Di Campli C; Moroncini G; Manzin A; Abrignani S; Varaldo PE; Clementi M; Fadda G
Virology; 2001 Sep; 288(1):29-35. PubMed ID: 11543655
[TBL] [Abstract][Full Text] [Related]
7. Isolation of human monoclonal antibodies to the envelope e2 protein of hepatitis C virus and their characterization.
Shimizu YK; Hijikata M; Oshima M; Shimizu K; Alter HJ; Purcell RH; Yoshikura H; Hotta H
PLoS One; 2013; 8(2):e55874. PubMed ID: 23409074
[TBL] [Abstract][Full Text] [Related]
8. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein.
Owsianka AM; Tarr AW; Keck ZY; Li TK; Witteveldt J; Adair R; Foung SKH; Ball JK; Patel AH
J Gen Virol; 2008 Mar; 89(Pt 3):653-659. PubMed ID: 18272755
[TBL] [Abstract][Full Text] [Related]
9. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein.
Perotti M; Mancini N; Diotti RA; Tarr AW; Ball JK; Owsianka A; Adair R; Patel AH; Clementi M; Burioni R
J Virol; 2008 Jan; 82(2):1047-52. PubMed ID: 17989176
[TBL] [Abstract][Full Text] [Related]
10. Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.
Keck ZY; Li SH; Xia J; von Hahn T; Balfe P; McKeating JA; Witteveldt J; Patel AH; Alter H; Rice CM; Foung SK
J Virol; 2009 Jun; 83(12):6149-60. PubMed ID: 19321602
[TBL] [Abstract][Full Text] [Related]
11. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity.
Schofield DJ; Bartosch B; Shimizu YK; Allander T; Alter HJ; Emerson SU; Cosset FL; Purcell RH
Hepatology; 2005 Nov; 42(5):1055-62. PubMed ID: 16250048
[TBL] [Abstract][Full Text] [Related]
12. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus.
Broering TJ; Garrity KA; Boatright NK; Sloan SE; Sandor F; Thomas WD; Szabo G; Finberg RW; Ambrosino DM; Babcock GJ
J Virol; 2009 Dec; 83(23):12473-82. PubMed ID: 19759151
[TBL] [Abstract][Full Text] [Related]
13. Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments.
Burioni R; Plaisant P; Manzin A; Rosa D; Delli Carri V; Bugli F; Solforosi L; Abrignani S; Varaldo PE; Fadda G; Clementi M
Hepatology; 1998 Sep; 28(3):810-4. PubMed ID: 9731577
[TBL] [Abstract][Full Text] [Related]
14. Combination of neutralizing monoclonal antibodies against Hepatitis C virus E2 protein effectively blocks virus infection.
Bose M; Mullick R; Das S; Das S; Karande AA
Virus Res; 2016 Sep; 224():46-57. PubMed ID: 27574733
[TBL] [Abstract][Full Text] [Related]
15. Conformational epitopes detected by cross-reactive antibodies to envelope 2 glycoprotein of the hepatitis C virus.
Nakano I; Fukuda Y; Katano Y; Hayakawa T
J Infect Dis; 1999 Oct; 180(4):1328-33. PubMed ID: 10479166
[TBL] [Abstract][Full Text] [Related]
16. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2.
Higginbottom A; Quinn ER; Kuo CC; Flint M; Wilson LH; Bianchi E; Nicosia A; Monk PN; McKeating JA; Levy S
J Virol; 2000 Apr; 74(8):3642-9. PubMed ID: 10729140
[TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of human monoclonal antibodies against hepatitis C virus envelope glycoproteins.
da Silva Cardoso M; Siemoneit K; Sturm D; Krone C; Moradpour D; Kubanek B
J Med Virol; 1998 May; 55(1):28-34. PubMed ID: 9580883
[TBL] [Abstract][Full Text] [Related]
18. Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.
Gopal R; Jackson K; Tzarum N; Kong L; Ettenger A; Guest J; Pfaff JM; Barnes T; Honda A; Giang E; Davidson E; Wilson IA; Doranz BJ; Law M
PLoS Pathog; 2017 Dec; 13(12):e1006735. PubMed ID: 29253863
[TBL] [Abstract][Full Text] [Related]
19. Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422.
Sandomenico A; Leonardi A; Berisio R; Sanguigno L; Focà G; Focà A; Ruggiero A; Doti N; Muscariello L; Barone D; Farina C; Owsianka A; Vitagliano L; Patel AH; Ruvo M
J Virol; 2016 Jan; 90(7):3745-59. PubMed ID: 26819303
[TBL] [Abstract][Full Text] [Related]
20. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins.
Shaw ML; McLauchlan J; Mills PR; Patel AH; McCruden EA
J Med Virol; 2003 Jul; 70(3):361-72. PubMed ID: 12766998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
